Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any
Updated:5/2/2018
Start Date:January 24, 2018
End Date:July 31, 2020
Contact:Eduardo Schiffrin, MD
Email:eduardo.schiffrin@ab2bio.com
Phone:+41 21 694 00 43

Use our guide to learn which trials are right for you!

Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd.
ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953). This OLE study will
evaluate the long-term safety and tolerability of Tadekinig alfa in patients suffering from
pediatric monogenic autoinflammatory diseases harboring deleterious mutations of NLRC4 and
XIAP.

Pediatric auto-inflammatory conditions related to spontaneous activating mutations of the
NLRC4 and with recurrent MAS-like flares with constitutive IL-18 hypersecretion, may require
long-term blockade of the IL-18 pathway.

Patients with X-linked inhibitor of apoptosis (XIAP) deficiency and suffering from
Hemophagocytic-Lymphohistiocytosis (HLH), a MAS-like syndrome, also show high levels of serum
IL-18 and may benefit from IL-18 blockade treatment until a curative hematopoietic stem cell
transplantation can be performed The safety of IL-18 blockade during long-term periods is of
major interest for the treatment of these patients

Inclusion Criteria: (both criteria must be met)

1. Patients have participated in AB2 Bio ltd. Phase III clinical trial
NLRC4/XIAP.2016.001 (IND N° 127953) by one of the following mechanisms : a) Patients
that have completed the first 18-week RCT phase of the preceding clinical trial but
were not eligible for the RW phase due to flare symptoms. Or b) Patients that
completed the first 18-week RCT phase and completed the RW phase of the preceding
clinical trial. Or c) Patients who have exited either the RCT or RW phase of the
preceding clinical trial due to treatment failure requiring rescue immunosuppression.
Such patients must wait a minimum of 4 weeks after treatment discontinuation from the
preceding clinical trial before enrolling in this OLE. If patients do not consent to
enroll in the OLE after their early termination in the main study, they will be asked
to continue with the planned visits of the main study

2. Women of childbearing potential with negative urine pregnancy test (UPT) at all visits

Exclusion Criteria:

1. Patients may not enter the OLE if they voluntarily withdrew from RCT or RW study or if
the time period between participation exceeds 3 months

2. Evidence or history of malignancy

3. Evidence of invasive or life-threatening infection

4. History of tuberculosis

5. Life-threatening bleeding within 2 weeks of screening

6. Vaccination with a live vaccine within the previous 3 months

7. Evidence of severe organ compromise including but not limited to: (see details in the
protocol)

8. Pregnant or breastfeeding females

9. Inability to follow highly effective birth control recommendations during the study
and until 1 month after the end of the treatment.

10. Inability to provide informed consent, and also assent if applicable

11. Life expectancy less than 4 weeks

12. Concomitant use of other immunosuppression except NSAIDs, glucocorticoids,
cyclosporine, tacrolimus, IL-1 inhibitors (Anakinra, Canakinumab, or Rilonacept)
We found this trial at
8
sites
Houston, Texas 77030
Phone: 832-824-1319
?
mi
from
Houston, TX
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-803-9063
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Phone: 412-692-9934
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1600 7th Avenue South
Birmingham, Alabama 35233
Phone: 205-996-7584
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Phone: 617-355-6117
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
3175 Chemin de la Côte-Sainte-Catherine
Montréal, H3T 1C5
Phone: 514-345-4931
?
mi
from
Montréal,
Click here to add this to my saved trials
3401 Civic Center Boulevard
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials